US 11,786,481 B2
Formulation and process for modulating wound healing
Chun-che Tsai, Kent, OH (US); Karen M. McGuire, Akron, OH (US); James M. Jamison, Cleveland Heights, OH (US); and Jack L. Summers, Sun City Center, FL (US)
Assigned to BioMendics, LLC, Fairlawn, OH (US)
Filed by BioMendics, LLC, Fairlawn, OH (US)
Filed on Apr. 2, 2021, as Appl. No. 17/221,181.
Application 17/221,181 is a continuation of application No. 16/584,195, filed on Sep. 26, 2019, abandoned.
Application 16/584,195 is a continuation of application No. 16/058,437, filed on Aug. 8, 2018, granted, now 10,426,742, issued on Oct. 1, 2019.
Application 16/058,437 is a continuation of application No. 15/093,146, filed on Apr. 7, 2016, granted, now 10,045,950, issued on Aug. 14, 2018.
Claims priority of provisional application 62/144,539, filed on Apr. 8, 2015.
Prior Publication US 2021/0228501 A1, Jul. 29, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/05 (2006.01); A61K 31/085 (2006.01); A61K 31/09 (2006.01); A61K 31/7034 (2006.01); A61K 45/06 (2006.01); A61K 9/06 (2006.01); A61K 47/36 (2006.01); A61K 47/40 (2006.01); A61Q 19/08 (2006.01); A61Q 7/00 (2006.01); A61K 8/34 (2006.01); A61K 8/33 (2006.01); A61K 8/60 (2006.01); A61K 8/73 (2006.01); A61K 8/67 (2006.01); A61K 9/00 (2006.01); A61K 9/08 (2006.01); A61K 9/19 (2006.01); A61K 8/70 (2006.01); A61K 31/03 (2006.01); A61K 31/167 (2006.01); A61K 31/375 (2006.01); A61K 31/655 (2006.01)
CPC A61K 31/05 (2013.01) [A61K 8/33 (2013.01); A61K 8/347 (2013.01); A61K 8/602 (2013.01); A61K 8/676 (2013.01); A61K 8/70 (2013.01); A61K 8/733 (2013.01); A61K 8/738 (2013.01); A61K 9/0019 (2013.01); A61K 9/06 (2013.01); A61K 9/08 (2013.01); A61K 9/19 (2013.01); A61K 31/03 (2013.01); A61K 31/085 (2013.01); A61K 31/09 (2013.01); A61K 31/167 (2013.01); A61K 31/375 (2013.01); A61K 31/655 (2013.01); A61K 31/7034 (2013.01); A61K 45/06 (2013.01); A61K 47/36 (2013.01); A61K 47/40 (2013.01); A61Q 7/00 (2013.01); A61Q 19/08 (2013.01); Y02A 50/30 (2018.01)] 23 Claims
OG exemplary drawing
 
1. A composition comprising a first autophagy modulating compound dispersed in a hydrogel, wherein the first autophagy modulating compound has the structure (I):

OG Complex Work Unit Chemistry
wherein L is a linker comprising —C≡C—;
R1 and R2 are independently substituents at any available position of the phenyl rings;
m and n are, independently, 0, 1, 2, or 3, representing the number of substituents on the rings, respectively, and at least one of m or n must be ≥1;
wherein each of R1 and R2 is independently selected from:
R5, wherein R5 is selected from (C1-C6)alkyl, (C2-C6)alkenyl, or (C2-C6)alkynyl, optionally substituted with 1 to 3 substituents selected from —OH, —SH, -halo, —NH2, or NO2;
YR6, wherein Y is O, S, or NH; and R6 is selected from H or R5;
ZR5, wherein Z is —N(C═O)— or —O(C═O)—;
halo;
NO2;
SO3Na;
azide; and
glycosides;
and salts thereof;
with the proviso that the first autophagy modulating compound is not resveratrol or 4,4′-(ethyne-1,2-diyl)diphenol (TOLECINE, also known as 4,4′-dihydroxytolan).